APO Research
Talk to an analyst

APO RESEARCH · REPORT

FAP Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global FAP Inhibitor Market Outlook and Growth Opportunities 2026

29 December 2025193 pages

Choose your research edition.

Industry ResearchFAP Inhibitor Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal FAP Inhibitor Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal FAP Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FAP Inhibitor Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal FAP Inhibitor Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global FAP Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for FAP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for FAP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for FAP Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the FAP Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the FAP Inhibitor market include SOFIE, Ferronova, GE HealthCare, Isotopia, Lantheus, Bayer and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global FAP Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of FAP Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents FAP Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the FAP Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

FAP Inhibitor Segment by Company

SOFIE

Ferronova

GE HealthCare

Isotopia

Lantheus

Bayer

Novartis AG

FAP Inhibitor Segment by Type

Ga-labeled

F-labeled

Other

FAP Inhibitor Segment by Application

Tumor Diagnosis

Tumor Treatment

Others

FAP Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global FAP Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions FAP Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify FAP Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze FAP Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FAP Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FAP Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FAP Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the FAP Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global FAP Inhibitor industry.

Chapter 3: Detailed analysis of FAP Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of FAP Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of FAP Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. FAP Inhibitor Industry Trends Table 2. FAP Inhibitor Industry Drivers Table 3. FAP Inhibitor Industry Opportunities and Challenges Table 4. FAP Inhibitor Industry Restraints Table 5. Global FAP Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global FAP Inhibitor Revenue Share by Company (2021-2026) Table 7. Global FAP Inhibitor Sales Volume by Company (K Units) & (2021-2026) Table 8. Global FAP Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global FAP Inhibitor Average Price (US$/Unit) of Company (2021-2026) Table 10. Global FAP Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global FAP Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global FAP Inhibitor Company, Product Type & Application Table 13. Global FAP Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global FAP Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ga-labeled Table 18. Significant Companies of F-labeled Table 19. Significant Companies of Other Table 20. Global FAP Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global FAP Inhibitor Sales Volume by Type (2021-2026) & (K Units) Table 22. Global FAP Inhibitor Sales Volume by Type (2027-2032) & (K Units) Table 23. Global FAP Inhibitor Sales Volume Share by Type (2021-2026) Table 24. Global FAP Inhibitor Sales Volume Share by Type (2027-2032) Table 25. Global FAP Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global FAP Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global FAP Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global FAP Inhibitor Sales Value Share by Type (2021-2026) Table 29. Global FAP Inhibitor Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Tumor Diagnosis Table 31. Significant Companies of Tumor Treatment Table 32. Significant Companies of Others Table 33. Global FAP Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global FAP Inhibitor Sales Volume by Application (2021-2026) & (K Units) Table 35. Global FAP Inhibitor Sales Volume by Application (2027-2032) & (K Units) Table 36. Global FAP Inhibitor Sales Volume Share by Application (2021-2026) Table 37. Global FAP Inhibitor Sales Volume Share by Application (2027-2032) Table 38. Global FAP Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global FAP Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global FAP Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global FAP Inhibitor Sales Value Share by Application (2021-2026) Table 42. Global FAP Inhibitor Sales Value Share by Application (2027-2032) Table 43. Global FAP Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global FAP Inhibitor Sales by Region (2021-2026) & (K Units) Table 45. Global FAP Inhibitor Sales Market Share by Region (2021-2026) Table 46. Global FAP Inhibitor Sales by Region (2027-2032) & (K Units) Table 47. Global FAP Inhibitor Sales Market Share by Region (2027-2032) Table 48. Global FAP Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global FAP Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global FAP Inhibitor Sales Value Share by Region (2021-2026) Table 51. Global FAP Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global FAP Inhibitor Sales Value Share by Region (2027-2032) Table 53. Global FAP Inhibitor Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global FAP Inhibitor Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global FAP Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global FAP Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global FAP Inhibitor Sales by Country (2021-2026) & (K Units) Table 58. Global FAP Inhibitor Sales Market Share by Country (2021-2026) Table 59. Global FAP Inhibitor Sales by Country (2027-2032) & (K Units) Table 60. Global FAP Inhibitor Sales Market Share by Country (2027-2032) Table 61. Global FAP Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global FAP Inhibitor Sales Value Market Share by Country (2021-2026) Table 63. Global FAP Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global FAP Inhibitor Sales Value Market Share by Country (2027-2032) Table 65. SOFIE Company Information Table 66. SOFIE Business Overview Table 67. SOFIE FAP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. SOFIE FAP Inhibitor Product Portfolio Table 69. SOFIE Recent Development Table 70. Ferronova Company Information Table 71. Ferronova Business Overview Table 72. Ferronova FAP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Ferronova FAP Inhibitor Product Portfolio Table 74. Ferronova Recent Development Table 75. GE HealthCare Company Information Table 76. GE HealthCare Business Overview Table 77. GE HealthCare FAP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. GE HealthCare FAP Inhibitor Product Portfolio Table 79. GE HealthCare Recent Development Table 80. Isotopia Company Information Table 81. Isotopia Business Overview Table 82. Isotopia FAP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Isotopia FAP Inhibitor Product Portfolio Table 84. Isotopia Recent Development Table 85. Lantheus Company Information Table 86. Lantheus Business Overview Table 87. Lantheus FAP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Lantheus FAP Inhibitor Product Portfolio Table 89. Lantheus Recent Development Table 90. Bayer Company Information Table 91. Bayer Business Overview Table 92. Bayer FAP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Bayer FAP Inhibitor Product Portfolio Table 94. Bayer Recent Development Table 95. Novartis AG Company Information Table 96. Novartis AG Business Overview Table 97. Novartis AG FAP Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Novartis AG FAP Inhibitor Product Portfolio Table 99. Novartis AG Recent Development Table 100. Key Raw Materials Table 101. Raw Materials Key Suppliers Table 102. FAP Inhibitor Distributors List Table 103. FAP Inhibitor Customers List Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. FAP Inhibitor Product Image Figure 2. Global FAP Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FAP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global FAP Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global FAP Inhibitor Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global FAP Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ga-labeled Image Figure 10. F-labeled Image Figure 11. Other Image Figure 12. Global FAP Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global FAP Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global FAP Inhibitor Sales Volume Share by Type (2021-2032) Figure 15. Global FAP Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global FAP Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global FAP Inhibitor Sales Value Share by Type (2021-2032) Figure 18. Tumor Diagnosis Image Figure 19. Tumor Treatment Image Figure 20. Others Image Figure 21. Global FAP Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global FAP Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global FAP Inhibitor Sales Volume Share by Application (2021-2032) Figure 24. Global FAP Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global FAP Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global FAP Inhibitor Sales Value Share by Application (2021-2032) Figure 27. Global FAP Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global FAP Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global FAP Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global FAP Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America FAP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 32. North America FAP Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe FAP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 34. Europe FAP Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific FAP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific FAP Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America FAP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 38. South America FAP Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa FAP Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa FAP Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt FAP Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt FAP Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt FAP Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. FAP Inhibitor Value Chain Figure 126. Manufacturing Cost Structure Figure 127. FAP Inhibitor Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Ga-labeled
  • F-labeled
  • Other
Applications
  • Tumor Diagnosis
  • Tumor Treatment
  • Others
Companies covered
  • SOFIE
  • Ferronova
  • GE HealthCare
  • Isotopia
  • Lantheus
  • Bayer
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global FAP Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global FAP Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global FAP Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 FAP Inhibitor Market Dynamics
  1. 2.1 FAP Inhibitor Industry Trends
  2. 2.2 FAP Inhibitor Industry Drivers
  3. 2.3 FAP Inhibitor Industry Opportunities and Challenges
  4. 2.4 FAP Inhibitor Industry Restraints
3 FAP Inhibitor Market by Company
  1. 3.1 Global FAP Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global FAP Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global FAP Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global FAP Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global FAP Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global FAP Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global FAP Inhibitor Company Product Type and Application
  8. 3.8 Global FAP Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global FAP Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 FAP Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 FAP Inhibitor Market by Type
  1. 4.1 FAP Inhibitor Type Introduction
  2. 4.1.1 Ga-labeled
  3. 4.1.2 F-labeled
  4. 4.1.3 Other
  5. 4.2 Global FAP Inhibitor Sales Volume by Type
  6. 4.2.1 Global FAP Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global FAP Inhibitor Sales Volume by Type (2021-2032)
  8. 4.2.3 Global FAP Inhibitor Sales Volume Share by Type (2021-2032)
  9. 4.3 Global FAP Inhibitor Sales Value by Type
  10. 4.3.1 Global FAP Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global FAP Inhibitor Sales Value by Type (2021-2032)
  12. 4.3.3 Global FAP Inhibitor Sales Value Share by Type (2021-2032)
5 FAP Inhibitor Market by Application
  1. 5.1 FAP Inhibitor Application Introduction
  2. 5.1.1 Tumor Diagnosis
  3. 5.1.2 Tumor Treatment
  4. 5.1.3 Others
  5. 5.2 Global FAP Inhibitor Sales Volume by Application
  6. 5.2.1 Global FAP Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global FAP Inhibitor Sales Volume by Application (2021-2032)
  8. 5.2.3 Global FAP Inhibitor Sales Volume Share by Application (2021-2032)
  9. 5.3 Global FAP Inhibitor Sales Value by Application
  10. 5.3.1 Global FAP Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global FAP Inhibitor Sales Value by Application (2021-2032)
  12. 5.3.3 Global FAP Inhibitor Sales Value Share by Application (2021-2032)
6 FAP Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global FAP Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global FAP Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global FAP Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global FAP Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global FAP Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global FAP Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global FAP Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global FAP Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global FAP Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America FAP Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America FAP Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe FAP Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe FAP Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific FAP Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific FAP Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America FAP Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America FAP Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa FAP Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa FAP Inhibitor Sales Value Share by Country, 2025 VS 2032
7 FAP Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global FAP Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global FAP Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global FAP Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global FAP Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global FAP Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global FAP Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global FAP Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global FAP Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA FAP Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada FAP Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico FAP Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany FAP Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France FAP Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. FAP Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy FAP Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain FAP Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia FAP Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands FAP Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries FAP Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China FAP Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan FAP Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea FAP Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India FAP Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia FAP Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia FAP Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil FAP Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina FAP Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile FAP Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia FAP Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru FAP Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia FAP Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel FAP Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE FAP Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey FAP Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran FAP Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt FAP Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt FAP Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt FAP Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 SOFIE
  2. 8.1.1 SOFIE Company Information
  3. 8.1.2 SOFIE Business Overview
  4. 8.1.3 SOFIE FAP Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 SOFIE FAP Inhibitor Product Portfolio
  6. 8.1.5 SOFIE Recent Developments
  7. 8.2 Ferronova
  8. 8.2.1 Ferronova Company Information
  9. 8.2.2 Ferronova Business Overview
  10. 8.2.3 Ferronova FAP Inhibitor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ferronova FAP Inhibitor Product Portfolio
  12. 8.2.5 Ferronova Recent Developments
  13. 8.3 GE HealthCare
  14. 8.3.1 GE HealthCare Company Information
  15. 8.3.2 GE HealthCare Business Overview
  16. 8.3.3 GE HealthCare FAP Inhibitor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GE HealthCare FAP Inhibitor Product Portfolio
  18. 8.3.5 GE HealthCare Recent Developments
  19. 8.4 Isotopia
  20. 8.4.1 Isotopia Company Information
  21. 8.4.2 Isotopia Business Overview
  22. 8.4.3 Isotopia FAP Inhibitor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Isotopia FAP Inhibitor Product Portfolio
  24. 8.4.5 Isotopia Recent Developments
  25. 8.5 Lantheus
  26. 8.5.1 Lantheus Company Information
  27. 8.5.2 Lantheus Business Overview
  28. 8.5.3 Lantheus FAP Inhibitor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lantheus FAP Inhibitor Product Portfolio
  30. 8.5.5 Lantheus Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer FAP Inhibitor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bayer FAP Inhibitor Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Novartis AG
  38. 8.7.1 Novartis AG Company Information
  39. 8.7.2 Novartis AG Business Overview
  40. 8.7.3 Novartis AG FAP Inhibitor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novartis AG FAP Inhibitor Product Portfolio
  42. 8.7.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 FAP Inhibitor Value Chain Analysis
  2. 9.1.1 FAP Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 FAP Inhibitor Sales Mode & Process
  6. 9.2 FAP Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 FAP Inhibitor Distributors
  9. 9.2.3 FAP Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst